UBS AG has given Symrise shares a "Buy" rating with a target price of 139 euros.
Charles Eden, an analyst, mentioned that the target for organic sales growth has increased, although he noted that organic growth in the third quarter was partly negative. This was due to high investor expectations following a strong performance from competitor Givaudan, which had an 11 percent increase in sales seen as a more realistic benchmark.
As of 10:27 am in the XETRA session, Symrise shares were trading at EUR 112.35, down 2.8 percent, indicating a potential upside of 23.72 percent relative to the target price. So far, 118,506 shares have been traded, and the stock has appreciated by 14.0 percent in 2024. Analysts are expecting the release of Q4 2024 earnings and sales figures on March 5, 2025.